A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

The FDA plans to introduce a faster approval process for custom gene-editing therapies, allowing combined trials for patients with related rare ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

Researchers at Washington University School of Medicine in St. Louis have identified central routes that two deadly viruses take to invade human cells and have designed decoy molecules that block the ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

Regarding market potential, I see it following an exponential curve, with forecasts indicating that by 2030, gene therapies and genetic corrections will become more widely available, potentially ...